Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Cancer or Locally Advanced”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03427814
What this trial is testing

Study of BGB-290 or Placebo in Participants With Advanced or Inoperable Gastric Cancer

Who this might be right for
Advanced or Inoperable Gastric Cancer
BeiGene 136
Large-scale testing (Phase 3)Study completedNCT01774721
What this trial is testing

ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.

Who this might be right for
Non-small Cell Lung Cancer With EGFR-Activating Mutations
Pfizer 452
Testing effectiveness (Phase 2)Looking for participantsNCT07189871
What this trial is testing

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

Who this might be right for
Castration-Resistant Prostate Cancer (CRPC)Colorectal CancerNSCLC (Non-small Cell Lung Cancer)+7 more
Radiopharm Theranostics, Ltd 61
Large-scale testing (Phase 3)Looking for participantsNCT05646862
What this trial is testing

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy

Who this might be right for
Breast Cancer
Hoffmann-La Roche 420
Large-scale testing (Phase 3)Study completedNCT00471146
What this trial is testing

Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.

Who this might be right for
Carcinoma, Pancreatic Ductal
Pfizer 630
Testing effectiveness (Phase 2)UnknownNCT04742153
What this trial is testing

MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Who this might be right for
Advanced or Metastatic Breast Cancer
Shanghai Miracogen Inc. 66
Testing effectiveness (Phase 2)Looking for participantsNCT06668103
What this trial is testing

Clinical Study of Combination Therapy With ABSK043 and Firmonertinib

Who this might be right for
Non-Small Cell Lung Cancer With EGFR Mutation
Abbisko Therapeutics Co, Ltd 54
Not applicableStudy completedNCT05902494
What this trial is testing

HER2 and LA/mUC: A Multi-country Chart Review Cohort Study

Who this might be right for
Urothelial Carcinoma
Seagen, a wholly owned subsidiary of Pfizer 389
Testing effectiveness (Phase 2)Study completedNCT00284141
What this trial is testing

Study of AVE0005 (VEGF Trap) in Locally Advanced or Metastatic Platinum- and Erlotinib- Resistant Non-small-cell-lung Adenocarcinoma

Who this might be right for
Pulmonary DiseasesNeoplasms, Lung
Sanofi 98
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06586294
What this trial is testing

Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma

Who this might be right for
Gastric AdenocarcinomaGastroesophageal Junction Adenocarcinoma
Akeso 294
Large-scale testing (Phase 3)Active Not RecruitingNCT06382142
What this trial is testing

A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer(PANKU-Breast02)

Who this might be right for
Triple-Negative Breast Cancer
Sichuan Baili Pharmaceutical Co., Ltd. 418
Large-scale testing (Phase 3)Looking for participantsNCT06927986
What this trial is testing

Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）

Who this might be right for
EGFR-mutated Locally Advanced or Metastatic NSCLC
CSPC Megalith Biopharmaceutical Co.,Ltd. 380
Large-scale testing (Phase 3)Active Not RecruitingNCT06519370
What this trial is testing

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Who this might be right for
Triple Negative Breast Cancer
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. 350
Post-approval studies (Phase 4)Study completedNCT00770588
What this trial is testing

Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa® 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
AstraZeneca 296
Large-scale testing (Phase 3)Looking for participantsNCT04400695
What this trial is testing

RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

Who this might be right for
Breast Cancer
RemeGen Co., Ltd. 366
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431
Testing effectiveness (Phase 2)Active Not RecruitingNCT04396821
What this trial is testing

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced CancerGastric CancerGastroesophageal-junction Cancer+1 more
Transcenta Therapeutics (Hangzhou) Co., Ltd. 150
Early research (Phase 1)Ended earlyNCT02110563
What this trial is testing

Phase I, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Solid Tumors, Multiple Myeloma, or Lymphoma

Who this might be right for
Solid TumorsMultiple MyelomaNon-Hodgkins Lymphoma+3 more
Dicerna Pharmaceuticals, Inc., a Novo Nordisk company 50
Early research (Phase 1)Ended earlyNCT02122146
What this trial is testing

PF-06664178 In Patients With Advanced Solid Tumors

Who this might be right for
Neoplasms
Pfizer 31
Not applicableActive Not RecruitingNCT06487156
What this trial is testing

Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb 404
Next Page